Home > Insider Trading > Filing (0001192482-21-000085)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1734919	R. Shirley Kuhlmann	C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072	Evp And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-19	45,360	$0.00	102,891	No	4	A	Direct
Common Stock	Acquisiton	2021-01-19	6,772	$0.00	109,663	No	4	A	Direct
Common Stock	Disposition	2021-01-20	6,081	$24.45	103,582	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Purchase)	Acquisiton	2021-01-19	129,600	$0.00	129,600	$24.06

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
129,600		2031-01-19	No	4	A	Direct

Footnotes

Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock.
On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 6,772 performance share units granted in two prior years.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer.